Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism

T(4) is standard treatment for hypothyroidism. A recent study reported that combined T(4)/liothyronine (T(3)) treatment improved well-being and cognitive function compared with T(4) alone. We conducted a double-blind, randomized, controlled trial with a crossover design in 110 patients (101 complete...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism Jg. 88; H. 10; S. 4543
Hauptverfasser: Walsh, John P, Shiels, Lauren, Lim, Ee Mun, Bhagat, Chotoo I, Ward, Lynley C, Stuckey, Bronwyn G A, Dhaliwal, Satvinder S, Chew, Gerard T, Bhagat, Minoti C, Cussons, Andrea J
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.10.2003
Schlagworte:
Adult
Blood Pressure - drug effects
Cognition - drug effects
Cross-Over Studies
Double-Blind Method
Drug Therapy, Combination
Female
Heart Rate - drug effects
Humans
Hypothyroidism - drug therapy
Hypothyroidism - psychology
Male
Middle Aged
Patient Compliance
Patient Satisfaction
Quality of Life
Reflex - drug effects
Thyroxine - administration & dosage
Thyroxine - blood
Triiodothyronine - administration & dosage
Triiodothyronine - blood
ISSN:0021-972X
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:T(4) is standard treatment for hypothyroidism. A recent study reported that combined T(4)/liothyronine (T(3)) treatment improved well-being and cognitive function compared with T(4) alone. We conducted a double-blind, randomized, controlled trial with a crossover design in 110 patients (101 completers) with primary hypothyroidism in which liothyronine 10 micro g was substituted for 50 micro g of the patients' usual T(4) dose. No significant (P < 0.05) difference between T(4) and combined T(4)/T(3) treatment was demonstrated on cognitive function, quality of life scores, Thyroid Symptom Questionnaire scores, subjective satisfaction with treatment, or eight of 10 visual analog scales assessing symptoms. For the General Health Questionnaire-28 and visual analog scales assessing anxiety and nausea, scores were significantly (P < 0.05) worse for combined treatment than for T(4) alone. Serum TSH was lower during T(4) treatment than during combined T(4)/T(3) treatment (mean +/- SEM, 1.5 +/- 0.2 vs. 3.1 +/- 0.2 mU/liter; P < 0.001), a potentially confounding factor; however, subgroup analysis of subjects with comparable serum TSH concentrations during each treatment showed no benefit from combined treatment compared with T(4) alone. We conclude that in the doses used in this study, combined T(4)/T(3) treatment does not improve well-being, cognitive function, or quality of life compared with T(4) alone.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0021-972X
DOI:10.1210/jc.2003-030249